Acute kidney allograft rejection remains a major complication in transplantation, with standard diagnostic methods such as serum creatinine monitoring lacking sufficient sensitivity and specificity. Researchers have developed a new non-invasive urine test based on metabolomic profiling that uses a specific constellation of metabolites (alanine, citrate, lactate and urea) to detect rejection. The UMBRELLA study analyzed 682 urine samples from 109 kidney transplant recipients and assessed 29 clinical parameters, including donor and recipient characteristics, ischemia times, and donor type. The research identified 10 significant confounders that affect the accuracy of the test, including lower residual urine volume, reduced eGFR, longer ischemia times, and certain HLA mismatches. The test achieved the highest diagnostic accuracy in living donor kidney recipients with an AUC of 0.720 (95% CI, 0.62–0.82), followed by recipients with short warm ischemia time (<30 minutes) with an AUC of 0.702 (95% CI, 0.61–0.79). The findings suggest a distinct metabolic profile in deceased-donor recipients during the first two weeks after transplantation. Understanding these influencing factors may increase the accuracy of noninvasive rejection detection and support early clinical interventions.